Iommi, Sabbath Play First Show Since Lymphoma Diagnosis

Tony Iommi, lead guitarist for Black Sabbath and current non-Hodgkin's lymphoma patient, played his first concert since receiving the diagnosis with his old band.

Black Sabbath performed together in a "long-awaited reunion" earlier this week at the O2 Academy Birmingham, not far from where the band was first formed several decades ago.

Despite the presence of Ozzy Osbourne, according to a Rolling Stone write-up of the show, the audience began an emotional chant of "Tony! Tony!" as the show began, in an obvious acknowledgement of his recent battle with the disease.

The heavy metal guitar legend first announced his lymphoma diagnosis back in early January of 2012. He has been undergoing unspecified treatments since February.

Source: Rolling Stone

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap